首页> 美国卫生研究院文献>Advances in Dermatology and Allergology/Postpy Dermatologii i Alergologii >The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
【2h】

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation

机译:暴露于生物学和靶向综合性疾病改性的妊娠和哺乳期的抗逆素药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic inflammatory diseases often affect women of childbearing age. Since biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are more available, their use during conception, pregnancy and lactation has become a matter of concern. Current studies prove the safety of innovative therapy in pregnant women and may contribute to its wider use than before in pregnancy and lactation. It mainly concerns tumour necrosis factor α (TNF-α) inhibitors. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. We present up-to-date knowledge of bDMARDs and tsDMARDs safety in pregnant and breastfeeding women.
机译:慢性炎症性疾病往往会影响育龄的妇女。由于生物学和靶向的合成疾病 - 改性抗触发药物(BDMARDS和TSDMARDS)更可用,因此它们在概念期间的使用,怀孕和哺乳期已经成为一个令人担忧的问题。目前的研究证明了孕妇创新疗法的安全性,可能导致其较广泛使用的妊娠和哺乳期。主要涉及肿瘤坏死因子α(TNF-α)抑制剂。我们使用医疗主题标题(网格)术语搜索PubMed并确定了相关的研究和指导方针。我们在怀孕和母乳喂养女性中展示了对BDMARDS和TSDMARDS安全的最新知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号